Nexus Pharmaceuticals Secures FDA Approval For Methylene Blue Injection

Nexus Pharmaceuticals, LLC has received FDA approval for its Methylene Blue Injection, USP. This medication is used to treat acquired methemoglobinemia, a condition affecting oxygen levels in the blood. The injection, available as 50 mg/10 mL (5 mg/mL) (0.5%), will be sold in cartons containing five single-dose 10 mL vials.‍

Sridhar Desikan, Chief Scientific Officer at Nexus Pharmaceuticals, said in a statement, “We are pleased to strengthen the supply of an AP-rated and TIAA compliant Methylene Blue Injection. The addition of Methylene Blue to our portfolio further emphasizes Nexus’ persistent ambition to provide life-saving medicine to those who need it most.”

Nexus Pharmaceuticals, LLC, a healthcare company in the U.S., focuses on creating specialty and generic drugs that are easier to use and require less effort to prepare. The company ensures its high-quality medicines address urgent medical needs and provide reliable, life-saving treatment options wherever they’re needed.